Broadening the Scope of Dyslipidemia Therapy by Targeting APOC3 (Apolipoprotein C3) and ANGPTL3 (Angiopoietin-Like Protein 3)

The positive relationship between increased levels of circulating triglycerides and cardiovascular events has been observed for decades. Driven by genetic cohort studies, inhibitors of APOC3 (apolipoprotein C3) and ANGPTL (angiopoietin-like protein) 3 that reduce circulating triglycerides are poised to enter clinical practice. We will review the biology of how inhibition of these 2 proteins affects circulating lipoproteins as well as the current state of clinical development of monoclonal antibodies, antisense oligonucleotides, and silencing RNAs targeting APOC3 and ANGPTL3.

Automated summary

The positive relationship between increased levels of circulating triglycerides and cardiovascular events has been observed for decades. Inhibitors of APOC3 and ANGPTL3 that reduce circulating triglycerides are poised to enter clinical practice, driven by genetic cohort studies. This review discusses the biology of how these inhibitors affect circulating lipoproteins and the current state of clinical development using monoclonal antibodies, antisense oligonucleotides, and silencing RNAs targeting APOC3 and ANGPTL3.